Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
All-case safety study of Remitro in relapsed or refractory peripheral and cutaneous T-cell lymphoma in Japan
jRCT2031220196Recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- May 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of denileukin diftitox in peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL), sponsored by Eisai Co., Ltd. Primary endpoints: Number of participants with adverse drug reactions and Number of participants with serious adverse drug reactions. Started May 2021; status: recruiting.
02
Drugs
denileukin diftitox
03
Conditions
peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on jRCT2031220196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220196.